Apixaban is sold under the brand name Eliquis [1]. The generic name for the medication is apixaban [1].
What is Apixaban used for?
Apixaban is a medication used to prevent strokes and systemic embolism in patients with non-valvular atrial fibrillation [2]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [2].
How does Apixaban work?
Apixaban is a direct factor Xa inhibitor [2]. It works by blocking the activity of factor Xa, a protein that plays a crucial role in the blood clotting cascade [3]. By inhibiting factor Xa, apixaban reduces thrombin generation and the formation of blood clots [3].
When does Apixaban's patent protection expire?
Patent expiration timelines for medications like apixaban can be complex and vary by region. Information on specific patent expiries can be found through resources that track drug patents. For detailed insights into apixaban's patent status and potential generic entry dates, DrugPatentWatch.com is a valuable resource [4].
Who manufactures Apixaban?
Apixaban is developed and marketed by Bristol Myers Squibb and Pfizer [1].
What are the potential side effects of Apixaban?
The most significant risk associated with apixaban is bleeding [2]. Other potential side effects include bruising, nosebleeds, and gastrointestinal bleeding [2]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there alternatives to Apixaban?
Other anticoagulant medications are available, including warfarin, dabigatran, rivaroxaban, and edoxaban [2]. The choice of anticoagulant depends on individual patient factors, including medical history and other conditions [2].
---
Cited Sources:
1. https://www.drugpatentwatch.com/drugs/apixaban
2. https://www.nhi.gov/drugs/apixaban
3. https://www.drugpatentwatch.com/blog/apixaban-mechanism-of-action
4. https://www.drugpatentwatch.com/